These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 1708317)

  • 61. Combined determination of serum CA 19-9 and tissue polypeptide antigen: why no improvement in pancreatic cancer diagnosis?
    Basso D; Fabris C; Del Favero G; Panucci A; Plebani M; Angonese C; Leandro G; Dodi G; Burlina A; Naccarato R
    Oncology; 1988; 45(1):24-9. PubMed ID: 3422390
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Correlations between serum trypsinogen-2 and pancreatic cancer.
    Cao J; Xia C; Cui T; Guo H; Li H; Ren Y; Wang S
    Hepatogastroenterology; 2015; 62(138):435-40. PubMed ID: 25916077
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Clinical evaluation of pancreatic cancer-associated mucin expressing CA19-9, CA50, Span-1, sialyl SSEA-1, and Dupan-2.
    Kawa S; Kato M; Oguchi H; Hsue GL; Kobayashi T; Koiwai T; Tokoo M; Furuta S; Ichikawa T; Kanai M
    Scand J Gastroenterol; 1992 Aug; 27(8):635-43. PubMed ID: 1359630
    [TBL] [Abstract][Full Text] [Related]  

  • 64. CA 494--a new tumor marker for the diagnosis of pancreatic cancer.
    Friess H; Büchler M; Auerbach B; Weber A; Malfertheiner P; Hammer K; Madry N; Greiner S; Bosslet K; Beger HG
    Int J Cancer; 1993 Mar; 53(5):759-63. PubMed ID: 8449599
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Serum procarboxypeptidase A and carboxypeptidase A levels in pancreatic disease.
    Kemik O; Kemik AS; Sumer A; Beğenik H; Dülger AC; Purisa S; Tuzun S
    Hum Exp Toxicol; 2012 May; 31(5):447-51. PubMed ID: 21502183
    [TBL] [Abstract][Full Text] [Related]  

  • 66. CA 19-9 in the differential diagnosis between pancreatic cancer and chronic pancreatitis.
    Farini R; Fabris C; Bonvicini P; Piccoli A; del Favero G; Venturini R; Panucci A; Naccarato R
    Eur J Cancer Clin Oncol; 1985 Apr; 21(4):429-32. PubMed ID: 3859414
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Evaluation of CEA, CA 19-9, CA-50, CA-195, and TATI with special reference to pancreatic disorders.
    Masson P; Pålsson B; Andren-Sandberg A
    Int J Pancreatol; 1991 May; 8(4):333-44. PubMed ID: 1791319
    [TBL] [Abstract][Full Text] [Related]  

  • 68. BAG3 is a novel serum biomarker for pancreatic adenocarcinomas.
    Falco A; Rosati A; Festa M; Basile A; De Marco M; d'Avenia M; Pascale M; Dal Piaz F; Tavano F; Di Mola FF; di Sebastiano P; Berloco PB; Nudo F; Caraglia M; Febbraro A; Barcaroli D; Scarpa A; Pezzilli R; De Laurenzi V; Turco MC
    Am J Gastroenterol; 2013 Jul; 108(7):1178-80. PubMed ID: 23821002
    [No Abstract]   [Full Text] [Related]  

  • 69. Tumour-associated trypsin inhibitor in the diagnosis of pancreatic carcinoma.
    Pasanen PA; Eskelinen M; Partanen K; Pikkarainen P; Penttilä I; Alhava E
    J Cancer Res Clin Oncol; 1994; 120(8):494-7. PubMed ID: 8207049
    [TBL] [Abstract][Full Text] [Related]  

  • 70. [Carbohydrate antigens CA 19-9, CA 242, CA 50 in liver diseases].
    Nowak J; Jakubowska D; Wiczkowski A; Sprzaczkowska K; Stechły T; Zmudziński W; Grzesik P; Walas R; Jarzab B
    Wiad Lek; 1998; 51(11-12):484-91. PubMed ID: 10222840
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Serum levels of CA 19-9 and CA 50 in relation to Lewis blood cell status in patients with malignant and benign pancreatic disease.
    von Rosen A; Linder S; Harmenberg U; Pegert S
    Pancreas; 1993 Mar; 8(2):160-5. PubMed ID: 8460090
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Value of ultrasonographic examination combined with measurement of serum tumor markers in the diagnosis of pancreatic cancer of less than 3 cm in diameter.
    Iishi H; Yamamura H; Tatsuta M; Okuda S; Kitamura T
    Cancer; 1986 May; 57(10):1947-51. PubMed ID: 3513940
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Rapid diagnosis of pancreatic cancer by combination of ultrasonography and serum tumour markers CA 19-9 and CA 50.
    Bovo P; Rigo L; Togni M; Montesi G; Di Francesco V; Brunori MP; Angelini G; Frulloni L; Marcori M; Cavallini G
    Ital J Gastroenterol; 1993; 25(9):477-81. PubMed ID: 8123894
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Tumour marker CA 50 levels compared to signs and symptoms in the diagnosis of pancreatic cancer.
    Pålsson B; Masson P; Andrén-Sandberg A
    Eur J Surg Oncol; 1997 Apr; 23(2):151-6. PubMed ID: 9158191
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Lysosomal aspartic and cysteine proteinases serum levels in patients with pancreatic cancer or pancreatitis.
    Leto G; Tumminello FM; Pizzolanti G; Montalto G; Soresi M; Carroccio A; Ippolito S; Gebbia N
    Pancreas; 1997 Jan; 14(1):22-7. PubMed ID: 8981503
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Artificial Intelligence Algorithm-Based Computerized Tomography Image Features Combined with Serum Tumor Markers for Diagnosis of Pancreatic Cancer.
    Qiao Z; Ge J; He W; Xu X; He J
    Comput Math Methods Med; 2022; 2022():8979404. PubMed ID: 35281945
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Effectiveness of discriminant analysis of serum CA 19-9 and elastase 1 in diagnosis of pancreatic carcinoma.
    Yamamura H; Tatsuta M; Ito M; Iishi H; Noguchi S; Okuda S; Yoshida M
    Pancreas; 1989; 4(4):401-5. PubMed ID: 2762270
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Can IL-2R alpha be a valuable marker along with CA 19-9 in the diagnosis of chronic pancreatitis and pancreatic cancer?
    Kayhan B; Kayhan B; Akdoğan M
    Int J Biol Markers; 2004; 19(3):196-202. PubMed ID: 15503821
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Tumour markers CA 19-9 and CA 50 in digestive tract malignancies.
    Haglund C; Roberts PJ; Jalanko H; Kuusela P
    Scand J Gastroenterol; 1992; 27(3):169-74. PubMed ID: 1502477
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Co-expression of human cancer-associated epitopes on mucin molecules.
    Lan MS; Bast RC; Colnaghi MI; Knapp RC; Colcher D; Schlom J; Metzgar RS
    Int J Cancer; 1987 Jan; 39(1):68-72. PubMed ID: 2432019
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.